Insider Selling Wave Sweeps High-Multiple Growth and Biotech Names

The session's filing flow was overwhelmingly one-directional. Snowflake director Benoit Dageville disclosed $16.79 million of stock sales, while Rhythm Pharmaceuticals executives Jennifer Lee and EVP Mazabraud sold $8.9 million and $6.6 million respectively. Krystal Biotech director Dino Rossi sold $8.2 million, Darling Ingredients EVP McNutt $536,720, and smaller disposals were logged at Corsair Gaming, Enphase Energy, Disc Medicine and Tectonic Therapeutic. Against that, the only reported purchase was Dutch Bros director Todd Penegor's $103,120 open-market buy. Individual sales frequently reflect pre-arranged 10b5-1 plans, diversification and option-expiry mechanics rather than directional conviction, and should not be read mechanically as bearish signals. But the aggregate ratio matters: when disclosed selling outweighs buying by more than two orders of magnitude in a single tape, it is consistent with insiders monetizing elevated valuations in the most richly priced pockets of software and clinical-stage biotech. Investors should track whether the pattern persists through the coming reporting window, particularly in names where sales are being executed above analyst price targets.